Macro Helix sent the below communication to all customers May 20, 2021. 

What's happening?

Monday May 17, 2021, HRSA announced that they sent letters to six pharmaceutical manufacturers regarding recent manufacturer actions. HRSA requested that the manufacturers provide an update to their policies. For more information about HRSA’s announcement click here.

Macro Helix is continuing to monitor the situation and working with vendors to prepare for possible scenarios.

What resources are available today?

340B Architect has two Admin reports to aid covered entities in evaluating potential impact to their 340B program from these manufacturer actions.

• Report (670) Manufacturer Inquiry Impact Report
  
  This HID-level report provides your covered entity with contract pharmacy 340B qualified prescription details to assess the financial impact of these manufacturers’ products on your 340B program based on the selected date range.

• NEW Report (693) Manufacturer Inquiry Impact Report Non-Qualified Scripts
  
  This HID-level report identifies all non-340B qualified prescriptions at contract pharmacies for these manufacturers including NDCs that you have placed on Do Not Order or the 340B Eligibility Exclusion lists. This report can also be used to help identify potentially missed 340B opportunity due to manufacturer actions.

 Together...We got this!

340B Our Macro Helix Support Team is ready to answer your questions and assist you with any changes within 340B Architect. You can reach support by calling 1-888-465-4526 or emailing support@macrohelix.com